Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Pyridam Farma Tbk Buyback Yield % Related Terms
PT Pyridam Farma Tbk Buyback Yield % Historical Data
* Premium members only.
The historical data trend for PT Pyridam Farma Tbk's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:PYFA vs ZTS, UTHR, VTRS: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Pyridam Farma Tbk's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Pyridam Farma Tbk Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Pyridam Farma Tbk's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where PT Pyridam Farma Tbk's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Pyridam Farma Tbk (ISX:PYFA) has a Buyback Yield % of 0.00 as of Jul. 26, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on PT Pyridam Farma Tbk and its competitors. According to the industry distribution chart, PT Pyridam Farma Tbk ranks #999999 out of 289 companies in the Drug Manufacturers industry.
Is PT Pyridam Farma Tbk's Buyback Yield % too high?
PT Pyridam Farma Tbk's current Buyback Yield % is 0.00. Based on the distribution chart, PT Pyridam Farma Tbk ranks #999999 out of 289 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PT Pyridam Farma Tbk has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PT Pyridam Farma Tbk's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Pyridam Farma Tbk ranks #999999 out of 289 companies for Buyback Yield %. This places PT Pyridam Farma Tbk in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on PT Pyridam Farma Tbk and its competitors. PT Pyridam Farma Tbk's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Pyridam Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk (ISX:PYFA) is currently considered Fairly Valued. The stock's GF Value™ is Rp211.99, compared to a current price of Rp206.00 — trading 2.8% below its estimated fair value. The current Buyback Yield % is 0.00. PT Pyridam Farma Tbk's overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For PT Pyridam Farma Tbk (ISX:PYFA), the current Buyback Yield % is 0.00 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Pyridam Farma Tbk (ISX:PYFA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk stock appears to be undervalued.
The current stock price of Rp206.00 is trading 2.8% below its estimated GF Value™ of Rp211.99.
GuruFocus considers PT Pyridam Farma Tbk to be Fairly Valued.
Key valuation signals for ISX:PYFA:
Buyback Yield %: 0.00
GF Value™: Rp211.99 vs. price of Rp206.00 (2.8% below fair value)
No single metric tells the full story. See the ISX:PYFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Pyridam Farma Tbk is engaged in the production and development of pharmaceutical medicines and the trading of medical equipment. It manufactures products namely Antibiotics, Vitamins, Supplements, and Traditional herbal care. It operates through two segments namely Pharmaceutical products, Esthetics, and Toll manufacturing services; and Medical equipment Products segment. The company derives maximum revenue from Pharmaceutical products, Esthetics, and Toll manufacturing services. The company's products include consumer health, Derma, prescription, and biomedilab.
67GF Score
Get the complete analysis for ISX:PYFA
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PYFA has been successfully added to your 
